|
gptkbp:instanceOf
|
gptkb:drug
DPP-4 inhibitor
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:ATCCode
|
A10BH02
|
|
gptkbp:bioavailability
|
85%
|
|
gptkbp:brand
|
gptkb:Galvus
gptkb:Eucreas
|
|
gptkbp:CASNumber
|
274901-16-5
|
|
gptkbp:chemicalClass
|
adamantane derivatives
|
|
gptkbp:combines
|
gptkb:metformin
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
severe hepatic impairment
|
|
gptkbp:developer
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
~3 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstPassMetabolism
|
minimal
|
|
gptkbp:form
|
gptkb:tablet
oral tablet
|
|
gptkbp:hasMolecularFormula
|
C17H25N3O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vildagliptin
|
|
gptkbp:interactsWith
|
other antidiabetic drugs
|
|
gptkbp:IUPACName
|
(S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
|
|
gptkbp:KEGGID
|
D07454
|
|
gptkbp:lactation
|
not recommended
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits dipeptidyl peptidase-4
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2019 (EU)
|
|
gptkbp:pregnancyCategory
|
B3 (Australia)
not recommended
|
|
gptkbp:proteinBinding
|
9.3%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL573
gptkb:DB04876
6918537
5293776
|
|
gptkbp:regulates
|
approved in EU
not approved in US
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
hypoglycemia (when combined with sulfonylureas)
|
|
gptkbp:storage
|
below 30°C
|
|
gptkbp:synonym
|
LAF237
|
|
gptkbp:UNII
|
20O93L6F9H
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|